TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00410150
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be treated with continuous albuterol nebs in oxygen
Study: NCT02108496
Drug: Intra-Articular Injections with Hyaluronic Acid (HA)
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Study: NCT04623996
Drug: TP-0184
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral dose
Study: NCT00401960
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
Study: NCT02978040
Drug: Cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
Study: NCT01872260
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg/day
Study: NCT02978040
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
Study: NCT02338466
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
Study: NCT02338466
Drug: tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg).
Study: NCT03173365
Drug: Brimonidine Tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
Study: NCT02415062
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23mg/day for 24 weeks versus 10mg/day for 24 weeks
Study: NCT02978040
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
Study: NCT01798537
Drug: Neomycin Colistin Nystatin Vancomycin
Normalized name: colistin / hydrocortisone / neomycin / thonzonium
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participating study arm patients will receive SDD from admission to discharge
Study: NCT01490047
Drug: Recombinant human TNF-α
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
Study: NCT01490047
Drug: Caelyx
Normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
Study: NCT01110668
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00178269
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01490047
Drug: Recombinant human TNF-α
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
Study: NCT04126993
Drug: Camrelizumab,
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT04126993
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT00504101
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
Study: NCT00504101
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
Study: NCT00504101
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
Study: NCT02301039
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03042572
Drug: Allogeneic Mesenchymal Stromal Cell
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
Study: NCT00147394
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04047303
Drug: CC-90010
Normalized name: Bet inhibitor cc-90010
DrugBank: Trotabresib (DB17421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90010
Study: NCT02676778
Drug: E7777
Normalized name: Elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00136851
Drug: amlodipine besylate/benazepril hydrochloride
Normalized name: Amlodipine Besylate/Benazepril Hydrochloride 5 MG-10 MG Oral Capsule
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00467558
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily
Study: NCT00467558
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT00992693
Drug: Ribavirin (Virazole) Injection
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60.
Study: NCT02776917
Drug: Cirmtuzumab + Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
Study: NCT00515879
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg
Study: NCT03537534
Drug: Lidocaine Jet Injector
Normalized name: lidocaine Jet Injector
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applying Lidocaine following endourologic procedure
Study: NCT03586284
Drug: Valganciclovir Hydrochloride
Normalized name: Valganciclovir Hydrochloride
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21 to 28 days of oral valganciclovir treatment
Study: NCT03586284
Drug: Ganciclovir Sodium
Normalized name: Ganciclovir Sodium
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 to 28 days of topical ganciclovir solution treatment
Study: NCT01612507
Drug: 600 mg Ceftaroline fosamil
Normalized name: ceftaroline fosamil 600 MG
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 h infusion
Study: NCT01612507
Drug: 600 mg Ceftaroline fosamil
Normalized name: ceftaroline fosamil 600 MG
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 h infusion
Study: NCT02304289
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Artesunate once-daily for 14 days, dose-escalation
Study: NCT01082393
Drug: topical tacrolimus treatment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 applications (day 1,day 3, day 6 and day10)
Study: NCT01082393
Drug: topical pimecrolimus treatment
Normalized name: pimecrolimus Topical Cream
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study: NCT01082393
Drug: local mometasone furoate treatment
Normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study: NCT01082393
Drug: cold cream
Normalized name: cold cream
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study: NCT00006220
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00310076
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
Study: NCT03197740
Drug: Donepezil patch
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment
Study: NCT03197740
Drug: aricept Tab
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT02974920
Drug: Rivaroxaban 10 MG
Normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 10 mg once daily for 180 days
Study: NCT02974920
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily for 180 days
Study: NCT02659059
Drug: Platinum Doublet Chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01702103
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04057300
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor tablet
Study: NCT04057300
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel tablet
Study: NCT04108481
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy
Study: NCT04586426
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered by subcutaneous (SC) injection.
Study: NCT04586426
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered by SC injection.
Study: NCT04586426
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered by SC injection.
Study: NCT00324363
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
Study: NCT02834624
Drug: Poractant alfa
Normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
Study: NCT02834624
Drug: calfactant
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
Study: NCT01412892
Drug: RAD001: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
Study: NCT00215943
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
Study: NCT00215943
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As outlined in Thalidomide and Dexamethasone Treatment arm
Study: NCT00215943
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As outlined in VAD Treatment Arm
Study: NCT00215943
Drug: adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As outlined in VAD Treatment arm
Study: NCT03332589
Drug: E6201 plus dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
Study: NCT01563445
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
Study: NCT01269190
Drug: Proflavine
Normalized name: proflavine
DrugBank: Proflavine (DB01123)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proflavine) used to stain the mouth tissue after initial imaging.
Study: NCT00108355
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
Study: NCT00108355
Drug: Midodrine
Normalized name: Midodrine
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine oral tablet at 10 mg three times a day.
Study: NCT00108355
Drug: Oral tablet (Midodrine placebo)
Normalized name: Oral Film
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet (Midodrine placebo) three times a day
Study: NCT00108355
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide LAR 20 mg intramuscular injection every 30 days
Study: NCT00108355
Drug: Saline injection (Octreotide LAR placebo)
Normalized name: octreotide
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Saline intramuscular injection 5 cc every 30 days.
Study: NCT04232085
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preparative regimen
Study: NCT04232085
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative regimen
Study: NCT04232085
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preparative regimen
Study: NCT04232085
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GVHD prophylaxis
Study: NCT04232085
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD prophylaxis
Study: NCT01773798
Drug: insulin degludec/insulin aspart 15
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
Study: NCT00466856
Drug: octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres
Study: NCT02164578
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02164578
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01773798
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
Study: NCT01773798
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
Study: NCT01717625
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
Study: NCT00507845
Drug: Ramipril-Felodipine
Normalized name: felodipine / ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
Study: NCT01773798
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
Study: NCT00160537
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01846156
Drug: MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
Study: NCT02109744
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02990845
Drug: Pembrolizumab/ Exemestane/ Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
Study: NCT01512355
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
Study: NCT01291524
Drug: Pregabalin controlled release, 330 mg, 400 to 500 calorie
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
Study: NCT01291524
Drug: Pregabalin controlled release, 330 mg, bedtime
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single oral dose of 330 mg controlled release tablet administered at bedtime
Study: NCT01291524
Drug: Pregabalin immediate release, 300 mg
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single oral dose of 300 mg immediate release capsule administered in the evening
Study: NCT03358485
Drug: Aolanti Weikang tablets
Normalized name: Atlantic mackerel
DrugBank: Atlantic mackerel (DB15542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
Study: NCT02079402
Drug: Isotonic crystalloids
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no